Roche and Genentech were unable to sufficiently demonstrate the benefit of using Columvi in an earlier treatment setting for ...

The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL ...

F. Hoffmann-La Roche Ltd. Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas 1,2. New data ...

Columvi is an intravenously administered bispecific T-cell engager (BiTE), targeting CD3 on T-cells and redirecting them to CD20-expressing cancer B cells, resulting in potent and selective T cell ...

Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response rate and a median duration of response of 1.5 years 1 Given over a fixed period of time, Columvi ...

(RTTNews) - Swiss drug major Roche Holding AG (RHHBY) announced Tuesday that the European Commission has granted conditional marketing authorisation for Columvi (glofitamab) to treat people with ...

Roche’s stock has lost 4.6% in the year so far compared with the industry’s decline of 1.6%.. Image Source: Zacks Investment Research Roche is evaluating Columvi in combination with other ...

Roche Canada and the pan-Canadian Pharmaceutical Alliance then successfully completed price negotiations for Columvi on July 22, 2024. Roche is proud to have worked closely with key organizations ...